Medication Use Evaluation of Dronedarone in Comparison to Amiodarone

Medication Use Evaluation of Dronedarone in Comparison to Amiodarone

Amiodarone is the most effective rhythm-control for atrial fibrillation, but produces serious potential side effects. Dronedarone was designed to eliminate amiodarone toxicities, but increased the risk of mortality in clinical trials. This medication use evaluation compares one year of dronedarone u...

ver descrição completa

Detalhes bibliográficos
Main Authors:	Adam Corey, Nita Johnston
Formato:	Artigo
Idioma:	English
Publicado em:	University of Minnesota Libraries Publishing 2016-12-01
Colecção:	INNOVATIONS in Pharmacy
Assuntos:	Dronedarone, Amiodarone, Medication Use Evaluation, Atrial Fibrillation
Acesso em linha:	https://pubs.lib.umn.edu/index.php/innovations/article/view/480

Registos relacionados

Comparison of Efficacy and Safety Between Dronedarone and Amiodarone Used During the Blind Period in Patients with Atrial Fibrillation After Catheter Ablation
Por: Li Y, et al.
Publicado em: (2023-12-01)

Cost-Effectiveness of Dronedarone and Amiodarone for the Treatment of Chinese Patients With Atrial Fibrillation
Por: Mengran Zhang, et al.
Publicado em: (2021-08-01)

Dronedarone and Amiodarone Induce Dyslipidemia and Thyroid Dysfunction in Rats
Por: Li-Qin Jiang, et al.
Publicado em: (2016-05-01)

Managing atrial fibrillation in the elderly: critical appraisal of dronedarone
Por: Trigo P, et al.
Publicado em: (2011-12-01)

Dronedarone — an antiarrythmic agent with new potential for atrial fibrillation treatment
Por: M. Yu. Gilyarov, et al.
Publicado em: (2010-12-01)

Dronedarone for the management of atrial fibrillation
Por: Swiss Medical Weekly
Publicado em: (2011-02-01)

Comparative effects of amiodarone and dronedarone treatments on cardiac function in a rabbit model
Por: Worakan Boonhoh, et al.
Publicado em: (2019-02-01)

Adverse drug reaction signals mining comparison of amiodarone and dronedarone: a pharmacovigilance study based on FAERS
Por: Ye Xu, et al.
Publicado em: (2024-10-01)

Simultaneous determination of amiodarone, dronedarone, and their principal metabolites in SD rat plasma by UPLC-MS/MS and its application in pharmacokinetics
Por: Ying Zhang, et al.
Publicado em: (2021-08-01)

Impact of dronedarone in atrial fibrillation and flutter on stroke reduction
Por: Christine Benn Christiansen, et al.
Publicado em: (2010-03-01)

THE USE OF AMIODARONE IN CLINICAL PRACTICE: THE PROBLEM OF SIDE EFFECTS
Por: O. V. Gaisenok
Publicado em: (2016-01-01)

Marked prolongation of QRS duration after initiation of dronedarone therapy
Por: Conrad Genz, et al.
Publicado em: (2014-08-01)

Bioavailability of dronedarone tablets administered with or without food in healthy participants
Por: Gerald V. Naccarelli, et al.
Publicado em: (2024-09-01)

Analysis of a Serious Adverse Reaction of Pulmonary Fibrosis Caused by Dronedarone
Por: Yuyan Chen, PM, et al.
Publicado em: (2024-01-01)

Dronedarone for Recurrent Ventricular Tachycardia: A Real Alternative?
Por: Victor Exposito, MD, et al.
Publicado em: (2012-03-01)

Medical conversion of heart rhythm with amiodarone in patients with atrial fibrillation
Por: A. G. Pronin, et al.
Publicado em: (2020-12-01)

CARDIAC ARRHYTHMIAS IN MEDICAL PRACTICE: CLINICAL CASE OF AMIODARONE-INDUCED THYROTOXICOSIS TYPE 2 AS A CAUSE OF RECURRENT ATRIAL FIBRILLATION
Por: O. V. Gaisenok
Publicado em: (2016-01-01)

Efficacy and speed of conversion of recent onset atrial fibrillation using oral propafenone versus parenteral amiodarone: A randomized controlled comparative study
Por: Hesham S. Taha, et al.
Publicado em: (2022-05-01)

Dronedarone-induced photoallergic reaction
Por: Levy Amar, PhD, et al.
Publicado em: (2020-12-01)

Evaluation of the Prophylactic Effect of Amiodarone in Reducing the Incidence of Post-CABG Atrial Fibrillation
Por: Niloofar Dadashpour, et al.
Publicado em: (2015-06-01)

NEW ANTIARRHYTHMIC DRUG FOR THE TREATMENT OF ATRIAL FIBRILLATION. STUDY DATA, CLINICAL GUIDELINES, REGULATORY AGENCY RECOMMENDATIONS
Por: S. Yu. Martsevich, et al.
Publicado em: (2016-01-01)

Electrophysiological and therapeutic effects of amiodarone in patients with preexcited atrial fibrillation
Por: Abolfath Alizadeh, et al.
Publicado em: (2022-01-01)

Comparative efficacy of amiodarone with ivabradin combination or amiodarone with bisoprolol combination in the prevention of atrial fibrillation recurrence in pa- tients with left ventricular diastolic dysfunction
Por: K. G. Adamyan, et al.
Publicado em: (2015-11-01)

Amiodarone-Induced Pulmonary Toxicity in a Patient With Paroxysmal Atrial Fibrillation and Recurrence of Pulmonary Toxicity
Por: Nuri Köse, et al.
Publicado em: (2022-01-01)

Amiodarone treatment investigation on the correlation between the drug sensitivity for paroxysmal atrial fibrillation and gene polymorphism
Por: Shuxin Hou, et al.
Publicado em: (2016-01-01)

Does prophylactic low-dose amiodarone decrease the incidence of postoperative atrial fibrillation after coronary artery bypass graft surgery? A randomized controlled trial
Por: Mohamed Ali Ahmed, et al.
Publicado em: (2022-09-01)

Transient Bradyarrhythmia A Sole Presentation of Amiodarone-Induced Hypothyroidism
Por: Gautam Jesrani, et al.
Publicado em: (2021-04-01)

Amiodarone pulmonary toxicity: Case report
Por: Vasić Nada, et al.
Publicado em: (2014-01-01)

Rhythm and rate control effects of intravenous amiodarone for atrial fibrillation complicated by acutely decompensated heart failure
Por: Daisuke Horiuchi, MD, et al.
Publicado em: (2014-06-01)

SIDE EFFECTS OF PROLONGED ANTIARRHYTHMIC THERAPY WITH AMIODARONE
Por: N P Dorofeeva, et al.
Publicado em: (2017-03-01)

Late-onset thyrotoxicosis after the cessation of amiodarone
Por: Melissa E. Middeldorp, et al.
Publicado em: (2020-11-01)

Evaluation of Amiodarone Administration in Patients with New-Onset Atrial Fibrillation in Septic Shock
Por: Andreea Oprea, et al.
Publicado em: (2024-09-01)

SAFETY OF AMIODARONE USAGE IN PATIENTS WITH WOLFF-PARKINSON-WHITE SYNDROME AND ATRIAL FIBRILLATION
Por: D. A. Kuzhel, et al.
Publicado em: (2016-01-01)

Case Report: Amiodarone-induced multi-organ toxicity
Por: Jingrui Yan, et al.
Publicado em: (2024-07-01)

PROSPECTS FOR THE TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION
Por: V. A. Sulimov, et al.
Publicado em: (2016-01-01)

Cardiomyocyte-Targeting Peptide to Deliver Amiodarone
Por: Maliha Zahid, et al.
Publicado em: (2023-08-01)

Digoxin and Amiodarone on the Risk of Ischemic Stroke in Atrial Fibrillation: An Observational Study
Por: Kuan-Cheng Lai, et al.
Publicado em: (2018-05-01)

A case of probable Amiodarone-induced pancreatitis in the treatment of atrial fibrillation: a literature review and case report
Por: Christopher J. Mercogliano, et al.
Publicado em: (2017-11-01)

The incidence of phlebitis development of high concentration of continuous amiodarone infusion with in-line filter compared to the low concentration without in-line filter: a retrospective propensity score-matched analysis
Por: Sirichai Cheewatanakornkul, et al.
Publicado em: (2022-08-01)

Local Use of Hydrogel with Amiodarone in Cardiac Surgery: Experiment and Translation to the Clinic
Por: Vladimir Shvartz, et al.
Publicado em: (2021-03-01)